PURPOSE: E-cadherin expression is diverse, and differences in patient characteristics may produce variability in expression. Whereas some studies have indicated that downregulation of e-cadherin, associated with loss of cellular adhesiveness, was correlative with poor prognosis and metastasis, other studies have failed to confirm this. The present study uses a highly homogenous population of patients at high-risk for breast cancer, on the basis of ethnic and socio-economic status, to examine the relationship between e-cadherin and other prognostic markers in breast cancer. METHODS: Immunohistochemical staining was undertaken for estrogen (ER) and progesterone (PR) receptors, epidermal growth factor receptor 2 (Her-2), p53, vascular endothelial factor (VEGF), and hypoxia inducible factor 1alpha (HIF-1alpha) and the levels of these markers was compared to e-cadherin expression in a high-risk African-American patient population. RESULTS: E-cadherin expression persisted into the later stagers of the disease, and was strongly associated with Her-2 and HIF-1alpha expression, but not p53, ER/PR or VEGF. CONCLUSIONS: In contrast to other studies on heterogeneous populations, e-cadherin is preserved in aggressive tumors in this high-risk population. The ethnic and socio-economic risk stratification needs to be accounted for in studies correlating markers and prognosis.
PURPOSE:E-cadherin expression is diverse, and differences in patient characteristics may produce variability in expression. Whereas some studies have indicated that downregulation of e-cadherin, associated with loss of cellular adhesiveness, was correlative with poor prognosis and metastasis, other studies have failed to confirm this. The present study uses a highly homogenous population of patients at high-risk for breast cancer, on the basis of ethnic and socio-economic status, to examine the relationship between e-cadherin and other prognostic markers in breast cancer. METHODS: Immunohistochemical staining was undertaken for estrogen (ER) and progesterone (PR) receptors, epidermal growth factor receptor 2 (Her-2), p53, vascular endothelial factor (VEGF), and hypoxia inducible factor 1alpha (HIF-1alpha) and the levels of these markers was compared to e-cadherin expression in a high-risk African-American patient population. RESULTS:E-cadherin expression persisted into the later stagers of the disease, and was strongly associated with Her-2 and HIF-1alpha expression, but not p53, ER/PR or VEGF. CONCLUSIONS: In contrast to other studies on heterogeneous populations, e-cadherin is preserved in aggressive tumors in this high-risk population. The ethnic and socio-economic risk stratification needs to be accounted for in studies correlating markers and prognosis.
Authors: H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza Journal: Cancer Res Date: 2000-03-15 Impact factor: 12.701
Authors: L Nakopoulou; H Gakiopoulou-Givalou; A J Karayiannakis; I Giannopoulou; A Keramopoulos; P Davaris; M Pignatelli Journal: Histopathology Date: 2002-06 Impact factor: 5.087
Authors: C G Colpaert; P B Vermeulen; I Benoy; A Soubry; F van Roy; P van Beest; G Goovaerts; L Y Dirix; P van Dam; S B Fox; A L Harris; E A van Marck Journal: Br J Cancer Date: 2003-03-10 Impact factor: 7.640
Authors: Mariel A Fanelli; Magdalena Montt-Guevara; Angela M Diblasi; Francisco E Gago; Olga Tello; F Darío Cuello-Carrión; Eduardo Callegari; Maria A Bausero; Daniel R Ciocca Journal: Cell Stress Chaperones Date: 2008-03-05 Impact factor: 3.667
Authors: P Querzoli; D Coradini; M Pedriali; P Boracchi; F Ambrogi; E Raimondi; R La Sorda; R Lattanzio; R Rinaldi; M Lunardi; C Frasson; F Modesti; S Ferretti; M Piantelli; S Iacobelli; E Biganzoli; I Nenci; S Alberti Journal: Br J Cancer Date: 2010-11-09 Impact factor: 7.640
Authors: Ana Catarina Figueira; Catarina Gomes; Joana Tavares de Oliveira; Hugo Vilhena; Júlio Carvalheira; Augusto J F de Matos; Patrícia Dias Pereira; Fátima Gärtner Journal: BMC Vet Res Date: 2014-11-26 Impact factor: 2.741
Authors: S Ghafoory; A Mehrabi; M Hafezi; X Cheng; K Breitkopf-Heinlein; M Hick; M Huichalaf; V Herbel; A Saffari; S Wölfl Journal: Oncogenesis Date: 2015-06-01 Impact factor: 7.485
Authors: José Roberto F Caldeira; Erika C Prando; Francisco C Quevedo; Francisco A Moraes Neto; Cláudia A Rainho; Silvia R Rogatto Journal: BMC Cancer Date: 2006-03-02 Impact factor: 4.430
Authors: Hanna M Peltonen; Annakaisa Haapasalo; Mikko Hiltunen; Vesa Kataja; Veli-Matti Kosma; Arto Mannermaa Journal: PLoS One Date: 2013-11-01 Impact factor: 3.240